Geroscience drugs
In human trials
Senolytics
Drugs that clear senescent “zombie” cells, with mixed but growing human data.
How it works
Senescent cells stop dividing but resist dying and release inflammatory signals (the SASP). Senolytics temporarily disable their survival pathways so they are cleared.
Hallmarks of aging targeted
Cellular senescence · Chronic inflammation
What the evidence says
Honest about what is proven, and what is not.
A small open-label study first showed dasatinib plus quercetin (D+Q) reduced senescent cells in human tissue (Hickson, EBioMedicine 2019). In a 60-woman phase 2 RCT, D+Q missed its primary bone endpoint, with benefit only in an exploratory high-senescence subgroup (Farr, Nat Med 2024). A 31-person RCT in fibrotic MASH reported fibrosis improvement in 47% vs 7% (Nat Metab 2026). Fisetin is still being evaluated in clinical trials; no senolytic is approved for aging.
Key reference
Farr JN, Atkinson EJ, Achenbach SJ, et al. Nat Med. 2024;30(9):2605-2612
Considering this for yourself?
Many longevity therapies are experimental, off-label or not FDA-approved for aging. A physician-guided evaluation weighs your labs, history and goals before anything is started.
Explore other emerging therapeutics
Foundations
Exercise and resistance training
The best-evidenced healthspan intervention we have: aerobic fitness plus strength.
Foundations
Sleep, nutrition and caloric restriction
Daily inputs that shape metabolic aging; the strongest data are for caloric restriction.
Metabolic
GLP-1 receptor agonists
Obesity and diabetes drugs with proven heart benefits and an open question on aging.